Virol J . Clinical evaluation of a fully automated and high-throughput molecular testing system for detection of influenza virus

[tetano]

Virol J


. 2022 Nov 16;19(1):188.
doi: 10.1186/s12985-022-01916-w.
Clinical evaluation of a fully automated and high-throughput molecular testing system for detection of influenza virus


Kosuke Kosai ¹ , Norihito Kaku ^{2 3} , Michiko Horie ⁴ , Hina Kodama ² , Norihiko Akamatsu ² , Yusuke Narita ⁵ , Yasushi Matsumoto ⁶ , Tetsuro Matsushita ⁷ , Yohei Mizuta ⁸ , Koichi Izumikawa ⁹ , Hiroshi Mukae ¹⁰ , Katsunori Yanagihara ^{2 3}



Affiliations

• PMID: 36384638
• DOI: 10.1186/s12985-022-01916-w

Free article

Abstract

Introduction: We investigated the performance of the cobas® 6800 system and cobas SARS-CoV-2 & Influenza A/B, a fully automated molecular testing system for influenza viruses and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This enabled an assay in a batch of 96 samples in approximately 3 h.
Methods: An assay was performed using the cobas SARS-CoV-2 & Influenza A/B on the cobas 6800 system for samples collected in four facilities between November 2019 and March 2020 in our previous study. The results were compared with those obtained using the reference methods.
Results: Of the 127 samples analyzed, the cobas SARS-CoV-2 & Influenza A/B detected influenza A virus in 75 samples, of which 73 were positive using the reference methods. No false negative results were observed. The overall positive and negative percent agreement for influenza A virus detection were 100.0% and 96.3%, respectively. There were no positive results for the influenza B virus or SARS-CoV-2.
Conclusion: The cobas 6800 system and cobas SARS-CoV-2 & Influenza A/B showed high accuracy for influenza A virus detection and can be useful for clinical laboratories, especially those that routinely assay many samples.

Keywords: Automated molecular assay; Batch assay; Nucleic acid amplification test; Respiratory virus.